237 related articles for article (PubMed ID: 25865556)
1. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Zhang PF; Li KS; Shen YH; Gao PT; Dong ZR; Cai JB; Zhang C; Huang XY; Tian MX; Hu ZQ; Gao DM; Fan J; Ke AW; Shi GM
Cell Death Dis; 2016 Apr; 7(4):e2201. PubMed ID: 27100895
[TBL] [Abstract][Full Text] [Related]
4. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
[TBL] [Abstract][Full Text] [Related]
5. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
8. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
Takeishi K; Taketomi A; Shirabe K; Toshima T; Motomura T; Ikegami T; Yoshizumi T; Sakane F; Maehara Y
J Hepatol; 2012 Jul; 57(1):77-83. PubMed ID: 22425622
[TBL] [Abstract][Full Text] [Related]
9. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
10. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
12. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
14. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
16. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression.
Wen W; Ding J; Sun W; Fu J; Chen Y; Wu K; Ning B; Han T; Huang L; Chen C; Xie D; Li Z; Feng G; Wu M; Xie W; Wang H
Hepatology; 2012 Jun; 55(6):1787-98. PubMed ID: 22271581
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
19. BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
Tang W; Xue R; Weng S; Wu J; Fang Y; Wang Y; Ji L; Hu T; Liu T; Huang X; Chen S; Shen X; Zhang S; Dong L
Int J Cancer; 2015 Mar; 136(6):E475-87. PubMed ID: 25196217
[TBL] [Abstract][Full Text] [Related]
20. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Delire B; Stärkel P
Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
